gefitinib has been researched along with herbimycin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (herbimycin) | Trials (herbimycin) | Recent Studies (post-2010) (herbimycin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 912 | 0 | 26 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariyama, H; Baba, E; Harada, M; Kusaba, H; Nakano, S; Qin, B; Tanaka, R | 1 |
1 other study(ies) available for gefitinib and herbimycin
| Article | Year |
|---|---|
Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gallbladder; Gefitinib; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rifabutin; Signal Transduction; Tyrosine | 2006 |